Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

BACKGROUND: The primary aim of this study was to evaluate the safety of a novel dendritic cell (DC) vaccine pulsed with survivin and MUC1, silenced with suppressor of cytokine signaling 1 (SOCS1), and immune stimulated with flagellin for patients with stage I to IIIA non-small cell lung cancer (NSCL...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Ge, Chunlei, Li, Ruilei, Song, Haifeng, Geng, Tao, Yang, Jinyan, Tan, Qinghua, Song, Linfeng, Wang, Ying, Xue, Yuanbo, Li, Zhen, Dong, Suwei, Zhang, Zhiwei, Zhang, Na, Guo, Jiyin, Hua, Lin, Chen, Siyi, Song, Xin
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5740508/
https://ncbi.nlm.nih.gov/pubmed/29268708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3859-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares